Bortezomib-induced peripheral neurotoxicity: A neurophysiological and pathological study in the rat

Experimental Neurology

Volumn 204, Issue 1, 2007, Pages 317-325

  Cavaletti, Guido ^a   Gilardini, Alessandra ^a   Canta, Annalisa ^a   Rigamonti, Laura ^a   Rodriguez Menendez, Virginia ^a   Ceresa, Cecilia ^a   Marmiroli, Paola ^a   Bossi, Mario ^a   Oggioni, Norberto ^a   D'Incalci, Maurizio ^b   De Coster, Roland ^c  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^c JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

Bortezomib; Dorsal root ganglia; Experimental; Peripheral neuropathy; Proteasome inhibitors; Rat

Indexed keywords

BORTEZOMIB; MYELIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL VACUOLE; CONTROLLED STUDY; CYTOPLASM; ELECTRON MICROSCOPY; ENDOPLASMIC RETICULUM; FEMALE; FOLLOW UP; KNOWLEDGE; MITOCHONDRION; MODEL; MORPHOLOGY; MORPHOMETRICS; NERVE FIBER DEGENERATION; NEUROPATHY; NEUROPHYSIOLOGY; NEUROTOXICITY; NONHUMAN; PATHOLOGY; PRIORITY JOURNAL; RAT; SATELLITE CELL; SCHWANN CELL; SCIATIC NERVE; SENSORY NERVE CONDUCTION; SPINAL CORD; SPINAL CORD NERVE CELL; SPINAL GANGLION; TAIL; WISTAR RAT;

ANIMALS; BORONIC ACIDS; FEMALE; GANGLIA, SPINAL; MICROSCOPY, ELECTRON; NEURAL CONDUCTION; NEURONS, AFFERENT; NEUROTOXINS; PERIPHERAL NERVOUS SYSTEM DISEASES; PYRAZINES; RATS; RATS, WISTAR; SCIATIC NERVE; SPINAL CORD; TAIL;

EID: 33847293709     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2006.11.010     Document Type: Article

References (36)

1. Cavaletti G., Tredici G., Marmiroli P., Petruccioli M.G., Barajon I., and Fabbrica D. Morphometric study of the sensory neuron and peripheral nerve changes induced by chronic cisplatin (DDP) administration in rats. Acta Neuropathol. (Berl) 84 (1992) 364-371
2. Cavaletti G., Cavalletti E., Montaguti P., Oggioni N., De Negri O., and Tredici G. Effect on the peripheral nervous system of the short-term intravenous administration of paclitaxel in the rat. Neurotoxicology 18 (1997) 137-145
3. Cavaletti G., Fabbrica D., Minoia C., Frattola L., and Tredici G. Carboplatin toxic effects on the peripheral nervous system of the rat. Ann. Oncol. 9 (1998) 443-447
4. Cavaletti G., Cavalletti E., Oggioni N., Sottani C., Minoia C., D'Incalci M., Zucchetti M., Marmiroli P., and Tredici G. Distribution of paclitaxel within the nervous system of the rat after repeated intravenous administration. Neurotoxicology 21 (2000) 389-393
5. Cavaletti G., Oggioni N., Sala F., Pezzoni G., Cavalletti E., Marmiroli P., Petruccioli M.G., Frattola L., and Tredici G. Effect on the peripheral nervous system of systemically administered dimethylsulfoxide in the rat: a neurophysiological and pathological study. Toxicol. Lett. 118 (2000) 103-107
6. Cavaletti G., Tredici G., Petruccioli M.G., Donde E., Tredici P., Marmiroli P., Minoia C., Ronchi A., Bayssas M., and Etienne G.G. Effects of different schedules of oxaliplatin treatment on the peripheral nervous system of the rat. Eur. J. Cancer 37 (2001) 2457-2463
7. Cece R., Petruccioli M.G., Pizzini G., Cavaletti G., and Tredici G. Ultrastructural aspects of DRG satellite cell involvement in experimental cisplatin neuronopathy. J. Submicrosc. Cytol. Pathol. 27 (1995) 417-425
8. Corsetti G., Rodella L., Rezzani R., Stacchiotti A., and Bianchi R. Cytoplasmic changes in satellite cells of spinal ganglia induced by cisplatin treatment in rats. Ultrastruct. Pathol. 24 (2000) 259-265
9. Desterro J.M., Rodriguez M.S., and Hay R.T. Regulation of transcription factors by protein degradation. Cell. Mol. Life Sci. 57 (2000) 1207-1219
10. Dispenzieri A. Bortezomib for myeloma-Much ado about something. N. Engl. J. Med. 352 (2005) 2546-2548
11. Dulic V., Kaufmann W.K., Wilson S.J., Tlsty T.D., Lees E., Harper J.W., Elledge S.J., and Reed S.I. p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell 76 (1994) 1013-1023
12. Durrant D., Liu J., Yang H.S., and Lee R.M. The bortezomib-induced mitochondrial damage is mediated by accumulation of active protein kinase C-delta. Biochem. Biophys. Res. Commun. 321 (2004) 905-908
13. Goy A., Younes A., McLaughlin P., Pro B., Romaguera J.E., Hagemeister F., Fayad L., Dang N.H., Samaniego F., Wang M., Broglio K., Samuels B., Gilles F., Sarris A.H., Hart S., Trehu E., Schenkein D., Cabanillas F., and Rodriguez A.M. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J. Clin. Oncol. 23 (2005) 667-675
14. Jagannath S., Barlogie B., Berenson J., Siegel D., Irwin D., Richardson P.G., Niesvizky R., Alexanian R., Limentani S.A., Alsina M., Adams J., Kauffman M., Esseltine D.L., Schenkein D.P., and Anderson K.C. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br. J. Haematol. 127 (2004) 165-172
15. King R.W., Deshaies R.J., Peters J.M., and Kirschner M.W. How proteolysis drives the cell cycle. Science 274 (1996) 1652-1659
16. Kondagunta G.V., Drucker B., Schwartz L., Bacik J., Marion S., Russo P., Mazumdar M., and Motzer R.J. Phase II trial of bortezomib for patients with advanced renal cell carcinoma. J. Clin. Oncol. 22 (2004) 3720-3725
17. 2+ is a critical determinant of Velcade (PS-341/bortezomib) cytotoxicity in myeloma cell lines. Cancer Res. 65 (2005) 3828-3836
18. Musto P., Falcone A., Sanpaolo G., Guglielmelli T., Zambello R., Balleari E., Catalano L., Spriano M., Cavallo F., La Sala A., Mantuano S., Nobile M., Melillo L., Scalzulli P.R., Dell'Olio M., Bodenizza C., Greco M.M., Carella Jr. A.M., Merla E., Carella A.M., Boccadoro M., Cascavilla N., and Palumbo A. Bortezomib (Velcade) for progressive myeloma after autologous stem cell transplantation and thalidomide. Leuk. Res. 30 (2006) 283-285
19. Musto P., Falcone A., Sanpaolo G., Guglielmelli T., Zambello R., Balleari E., Catalano L., Spriano M., Cavallo F., Sala A.L., Mantuano S., Nobile M., Melillo L., Scalzulli P.R., Dell'olio M., Bodenizza C., Greco M.M., Carella Jr. A.M., Merla E., Carella A.M., Boccadoro M., Cascavilla N., and Palumbo A. Bortezomib (Velcade) for progressive myeloma after autologous stem cell transplantation and thalidomide. Leuk. Res. 30 (2006) 283-285
20. Orlowski R.Z. The role of the ubiquitin-proteasome pathway in apoptosis. Cell Death Differ. 6 (1999) 303-313
21. Orlowski R.Z. Bortezomib and its role in the management of patients with multiple myeloma. Expert. Rev. Anticancer Ther. 4 (2004) 171-179
22. Orlowski R.Z., Voorhees P.M., Garcia R.A., Hall M.D., Kudrik F.J., Allred T., Johri A.R., Jones P.E., Ivanova A., Van Deventer H.W., Gabriel D.A., Shea T.C., Mitchell B.S., Adams J., Esseltine D.L., Trehu E.G., Green M., Lehman M.J., Natoli S., Collins J.M., Lindley C.M., and Dees E.C. Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. Blood 105 (2005) 3058-3065
23. Pei X.Y., Dai Y., and Grant S. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors. Clin. Cancer Res. 10 (2004) 3839-3852
24. Persohn E., Canta A., Schoepfer S., Traebert M., Mueller L., Gilardini A., Galbiati S., Nicolini G., Scuteri A., Lanzani F., Giussani G., and Cavaletti G. Morphological and morphometric analysis of paclitaxel and docetaxel-induced peripheral neuropathy in rats. Eur. J. Cancer 41 (2005) 1460-1466
25. Pisano C., Pratesi G., Laccabue D., Zunino F., Lo Giudice P., Bellucci A., Pacifici L., Camerini B., Vesci L., Castorina M., Cicuzza S., Tredici G., Marmiroli P., Nicolini G., Galbiati S., Calvani M., Carminati P., and Cavaletti G. Paclitaxel and cisplatin-induced neurotoxicity: a protective role of acetyl-l-carnitine. Clin. Cancer Res. 9 (2003) 5756-5767
26. Qin J.Z., Ziffra J., Stennett L., Bodner B., Bonish B.K., Chaturvedi V., Bennett F., Pollock P.M., Trent J.M., Hendrix M.J., Rizzo P., Miele L., and Nickoloff B.J. Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells. Cancer Res. 65 (2005) 6282-6293
27. Read M.A., Neish A.S., Luscinskas F.W., Palombella V.J., Maniatis T., and Collins T. The proteasome pathway is required for cytokine-induced endothelial-leukocyte adhesion molecule expression. Immunity 2 (1995) 493-506
28. Richardson P.G., Barlogie B., Berenson J., Singhal S., Jagannath S., Irwin D., Rajkumar S.V., Srkalovic G., Alsina M., Alexanian R., Siegel D., Orlowski R.Z., Kuter D., Limentani S.A., Lee S., Hideshima T., Esseltine D.L., Kauffman M., Adams J., Schenkein D.P., and Anderson K.C. A phase 2 study of bortezomib in relapsed, refractory myeloma. N. Engl. J. Med. 348 (2003) 2609-2617
29. Richardson P.G., Sonneveld P., Schuster M.W., Irwin D., Stadtmauer E.A., Facon T., Harousseau J.L., Ben-Yehuda D., Lonial S., Goldschmidt H., Reece D., San-Miguel J.F., Blade J., Boccadoro M., Cavenagh J., Dalton W.S., Boral A.L., Esseltine D.L., Porter J.B., Schenkein D., and Anderson K.C. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N. Engl. J. Med. 352 (2005) 2487-2498
30. Richardson P.G., Briemberg H., Jagannath S., Wen P.Y., Barlogie B., Berenson J., Singhal S., Siegel D.S., Irwin D., Schuster M., Srkalovic G., Alexanian R., Rajkumar S.V., Limentani S., Alsina M., Orlowski R.Z., Najarian K., Esseltine D., Anderson K.C., and Amato A.A. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J. Clin. Oncol. (2006)
31. San Miguel J., Blade J., Boccadoro M., Cavenagh J., Glasmacher A., Jagannath S., Lonial S., Orlowski R.Z., Sonneveld P., and Ludwig H. A practical update on the use of bortezomib in the management of multiple myeloma. Oncologist 11 (2006) 51-61
32. Shah M.H., Young D., Kindler H.L., Webb I., Kleiber B., Wright J., and Grever M. Phase II study of the proteasome inhibitor bortezomib (PS-341) in patients with metastatic neuroendocrine tumors. Clin. Cancer Res. 10 (2004) 6111-6118
33. ter Laak M.P., Hamers F.P., Kirk C.J., and Gispen W.H. rhGGF2 protects against cisplatin-induced neuropathy in the rat. J. Neurosci. Res. 60 (2000) 237-244
34. Tredici G., Braga M., Nicolini G., Miloso M., Marmiroli P., Schenone A., Nobbio L., Frattola L., and Cavaletti G. Effect of recombinant human nerve growth factor on cisplatin neurotoxicity in rats. Exp. Neurol. 159 (1999) 551-558
35. Voorhees P.M., Dees E.C., O'Neil B., and Orlowski R.Z. The proteasome as a target for cancer therapy. Clin. Cancer Res. 9 (2003) 6316-6325
36. Yu C., Rahmani M., Conrad D., Subler M., Dent P., and Grant S. The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571. Blood 102 (2003) 3765-3774